Abcam, ab205921, Anti-PD-L1 antibody [28-8]

Size: 20µL / 50µL
Anti-PD-L1 antibody [28-8] (ab205921) is a rabbit monoclonal antibody detecting PD-L1 in Western Blot, Flow Cytometry, IHC-P, IHC-Fr, ICC/IF, mIHC . Suitable for Human . - KO validated for confirmed specificity - Multiplex IHC validated on the Leica BOND® MAX using Opal reagents - Biophysical QC for unrivalled batch-batch consistency - Over 470 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:28-8,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, Flow Cyt, WB, mIHC, IHC-P, IHC-FrSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Anti-PD-L1 antibody [28-8] (ab205921) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt, ICC/IF, IHC-Fr, IHC-P, WB, mIHC in human samples.
Anti-PD-L1 antibody [28-8] (ab205921) has been cited over 476 times in peer reviewed journals and is trusted by the scientific community.
Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [28-8] (ab205921) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
The specificity of Anti-PD-L1 antibody [28-8] (ab205921) has been confirmed by testing in knockout samples.
Anti-PD-L1 antibody [28-8] (ab205921) has 13 independent reviews from customers.
Anti-PD-L1 antibody [28-8] (ab205921) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 31kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (50 µL).
Conjugation-ready, carrier free format available for antibody clone 28-8 -
ab228413
Antibody clone 28-8 is also available pre-conjugated to a variety of labels for your convenience - HRP, PE, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, FITC (
ab209961
ab209962
ab213358
ab213359
ab213360
ab224027
PD-L1 (Programmed Death-Ligand 1) is a protein that plays a significant role in oncology, particularly in the immune response to cancer. It is expressed on the surface of cancer cells and interacts with the PD-1 receptor on T-cells, effectively inhibiting the immune system's ability to attack the tumor. This interaction is a key target for immunotherapy drugs, such as checkpoint inhibitors, which block the PD-1/PD-L1 pathway, allowing the immune system to recognize and destroy cancer cells.
FURTHER INFORMATION ON POSITIVE CONTROLS (
Chinese version
Tissue:
- Tonsil - with hyperreactive changes. Screening of hyper-reactive tonsils is recommended to find tonsil with the highest expression of PD-L1 in crypt epithelium, macrophages homing the germinal centers and interfollicular mononuclear leukocytes.
- Tumor tissues - prescreened for positive tumor and inflammatory infiltrates. PD-L1 expression varies by tumor type so screening is recommended to find positive and negative tumor controls.
- The following publication is useful for finding suitable tumor types for PD-L1 expression:
http://www.immunotherapyofcancer.org/content/1/S1/P53
- Note: Look for specimens with high numbers of inflammatory macrophages and mononuclear leukocytes.
Cell Lines:
- Positive controls: B-CPAP (high), ES-2 (medium), HCC70 (low).
Primary antibody negative control:
Recombinant Rabbit IgG isotype control antibody,
ab172730
Recombinant protein positive control:
Recombinant human PD-L1 protein,
ab167713
Immunohistochemistry usage:
For IHC usage on FFPE tissues, we recommend using PD-L1 IHC panel
ab236676
, which contains PD-L1 antibody clone 28-8 (ab205921), HIER antigen retrieval reagent (
ab208572
) and IHC detection kit HRP/DAB (
ab209101
Western blot usage:
For clone 28-8, it is recommended to use Odyssey system. This system has the advantages of a wider dynamic range and less background than chemiluminescence.
This PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA
kit: ab214565 and
ab277712
To support you in your biomarker discovery and validation studies, we offer a
comprehensive suite of solutions
including high quality, validated recombinant antibodies and assay kits.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PD-L1 also known as programmed death-ligand 1 or CD274 plays an important role in the immune system. It is a protein expressed on antigen-presenting cells and some tumor cells helping them interact with T-cells. The molecular weight of PD-L1 is approximately 33 kDa. PD-L1 expression can occur in various tissues and is often upregulated in tumor microenvironments. This increased expression helps tumors evade the immune response.
Biological function summary
PD-L1 modulates the immune response by interacting with its receptor PD-1 on T-cells and other immune cells leading to immune suppression. It is part of the PD-1/PD-L1 complex an important regulator of T-cell activity and immune tolerance. The binding of PD-L1 to PD-1 inhibits T-cell proliferation and cytokine production reducing the ability of the immune system to attack cancer cells.
Pathways
PD-L1 is involved in the immune checkpoint pathway and the cancer immunity cycle. Its interaction with PD-1 influences important signaling cascades within these pathways affecting the immune system's capacity to target tumor cells effectively. Another protein important in this context is CTLA-4 another immune checkpoint regulator which along with PD-1 modulates immune system activity against cancer.
PD-L1 has strong connections to cancer and autoimmune diseases. Many cancers including melanoma and non-small cell lung cancer exploit PD-L1 to protect themselves from the immune system. Increased PD-L1 expression can also impact autoimmune disorders where the immune system reacts against healthy body tissues. This interaction further involves PD-1 and CTLA-4 illustrating their shared roles in these disease contexts.